N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration

Tissue Engineering - Part A

Volumn 15, Issue 10, 2009, Pages 2955-2963

  Miguel, Blanca San ^a   Ghayor, Chafik ^a   Ehrbar, Martin ^a   Jung, Ronald E ^b   Zwahlen, Roger A ^a   Hortschansky, Peter ^c   Schmoekel, Hugo G ^d   Weber, Franz E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c HANS KNÖLL INSTITUTE   (Germany)

^d Great Western Referrals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMICAL CONTAMINATION; PHOSPHATASES; PHOSPHORYLATION; STEM CELLS; TISSUE ENGINEERING;

ALKALINE PHOSPHATASE ACTIVITY; BMP RECEPTORS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE TISSUE REGENERATION; CALVARIAL DEFECTS; CELLULAR LEVELS; ECTODOMAIN; EXTRACELLULAR; FOOD AND DRUG ADMINISTRATION; HUMAN BONE MARROW; IN-VITRO; IN-VIVO; KINASE ACTIVITY; MEDICAL DEVICES; MODE OF ACTION; MOLECULAR LEVELS; MULTIPOTENT CELLS; N-METHYLPYRROLIDONE; OSTEOBLAST MATURATION; OSTEOGENIC; POTENT DRUGS; PREOSTEOBLASTS; TRACK RECORD; TRANSDIFFERENTIATION;

BONE;

ORYCTOLAGUS CUNICULUS;

2 PYRROLIDONE DERIVATIVE; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2;

ANIMAL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE REGENERATION; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENETIC PROCEDURES; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKULL; STROMA CELL; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; BIOSENSING TECHNIQUES; BLOTTING, WESTERN; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; HUMANS; MICE; OSTEOGENESIS; PHOSPHORYLATION; PYRROLIDINONES; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKULL; STROMAL CELLS;

EID: 73349114356     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2009.0009     Document Type: Article

References (35)

1. Urist, M.R. Bone: formation by autoinduction. 1965. Clin Orthop Rel Res 4, 2002.
2. Sebald, W., Nickel, J., Zhang, J.-L., and Mueller, T.D. Mole-cular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 385, 697, 2004.
3. Shi, Y., and Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685, 2003.
4. Nohe, A., Hassel, S., Ehrlich, M., Neubauer, F., Sebald, W., Henis, Y.I., and Knaus, P. The mode of bone morpho-genetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277, 5330, 2002.
5. Hassel, S., Yakymovych, M., Hellman, U., Ronnstrand, L., Knaus, P., and Souchelnytskyi, S. Interaction and functional cooperation between the serine/threonine kinase bone mor-phogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor. J Cell Physiol 206, 457, 2006.
6. Hassel, S., Eichner, A., Yakymovych, M., Hellman, U., Knaus, P., and Souchelnytskyi, S. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 4, 1346, 2004.
7. Groppe, J., Greenwald, J., Wiater, E., Rodriguez-Leon, J., Economides, A.N., Kwiatkowski, W., Affolter, M., Vale, W.W., Belmonte, J.C., and Choe, S. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420,636,2002.
8. Canalis, E., Economides, AN., Gazzerro, E., Canalis, E., Econ-omides, A.N., and Gazzerro, E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24, 218, 2003.
9. Schmitt, J.M., Hwang, K., Winn, S.R., and Hollinger, J.O. Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res 17, 269, 1999.
10. Jadlowiec, J.A., Celil, A.B., and Hollinger, J.O. Bone tissue engineering: recent advances and promising therapeutic agents. Expert Opin Biol Ther 3, 409, 2003.
11. Lutolf, M.P., Weber, F.E., Schmoekel, H.G., Schense, J.C., Kohler, T., Muller, R., and Hubbell, J.A. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 21, 513, 2003.
12. Pratt, A.B., Weber, F.E., Schmoekel, H.G., Muller, R., and Hubbell, J.A. Synthetic extracellular matrices for in situ Tissue engineering. Biotechnol Bioeng 86, 27, 2004.
13. Jung, R.E., Glauser, R., Scharer, P., Hammerle, C.H., Sailer, H.F., and Weber, F.E. Effect of rhBMP-2 on guided bone re-generation in humans. Clin Oral Implants Res 14,556, 2003.
14. Hammerle, C.H., and Jung, R.E. Bone augmentation by means of barrier membranes. Periodontology 2000 33, 36, 2003.
15. Pirhonen, E.M., Pohjonen, T.H., and Weber, F.E. Novel membrane for guided bone regeneration. International J Artif Organs 29, 834, 2006.
16. Jung, R.E., Schmoekel, H.G., Zwahlen, R., Kokovic, V., Hammerle, C.H.F., and Weber, F.E. Platelet-rich plasma and fibrin as delivery systems for recombinant human bone mor-phogenetic protein-2. Clin Oral Implants Res 16, 676, 2005.
17. Lee-Chuan, C., Yeh, A.D., Tsai, M.C., Zavala, J., and Lee, C. Cartilage-derived morphogenetic proteins enhance the os-teogenic protein-1-induced osteoblastic cell differentiation of C2C12 cells. J Cellular Physiology 201, 401, 2004.
18. Meinel, L., Karageorgiou, V., Hofmann, S., Fajardo, R., Snyder, B., Li, C., Zichner, L., Langer, R., Vunjak-Novakovic, G., and Kaplan, D.L. Engineering bone-like tissue in vitro using human bone marrow stem cells and silk scaffolds. J Biomedical Materials Research Part A 71A, 25, 2004.
19. Weber, F.E., Eyrich, G., Gratz, K.W., Thomas, R.M., Maly, F.E., and Sailer, H.F. Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochemical and Biophysical Research Communications 286, 554, 2001.
20. Weber, F.E., Schmokel, H., Oelgeschlager, M., Nickel, J., Maly, F.E., Hortschansky, P., and Gratz, K.W. Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification. J Bone and Mineral Research: the Official J the American Society For Bone and Mineral Research 18, 2142, 2003.
21. Guicheux, J., Lemonnier, J., Ghayor, C., Suzuki, A., Palmer, G., and Caverzasio, J. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 18, 2060, 2003.
22. Ghayor, C., Rey, A., and Caverzasio, J. Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor beta in mouse oste-oblastic cells. Bone 36, 93, 2005.
23. Lemonnier, J., Ghayor, C., Guicheux, J., and Caverzasio, J. Protein kinase C-independent activation of protein kinase D is involved in BMP-2-induced activation of stress mitogen-activated protein kinases JNK and p38 and osteoblastic cell differentiation. J Biol Chem 279, 259, 2004.
24. Weber, F.E., Schmökel, H.G., Pirhonen, E., Jung, R.E., and Grätz, K. The first bioactive degradable membrane for guided bone regeneration. IADR abstract book for Göteborg, J Dent Res 82(Spec Iss B) 1854, 2003.
25. Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., and de Crombrugghe, B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17,2002.
26. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J.M., Fujisawa-Sehara, A., Suda, T., Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J.M., Fujisawa-Sehara, A., and Suda, T. Bone morphoge-netic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. [erratum ap-pears in J Cell Biol 128,1995, following 713]. J Cell Biol 127, 1755, 1994.
27. Kirsch, T., Nickel, J., and Sebald, W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. Embo J 19, 3314, 2000.
28. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621, 2006.
29. Krebsbach, P.H., Kuznetsov, S.A., Bianco, P., and Gehron Robey, P. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral Biol Med 10, 165, 1999.
30. Wells, D.A., Hawi, A.A., and Digenis, G.A. Isolation and identification of the major urinary metabolite of N-methylpyrrolidinone in the rat. Drug Metab Dispos 20, 124, 1992.
31. Akesson, B., and Jonsson, B.A. Major metabolic pathway for N-methyl-2-pyrrolidone in humans. Drug Metab Dispos 25, 267, 1997.
32. Massague, J. TGF-beta signal transduction. Annu Rev Bio-chem 67, 753, 1998.
33. Nohe, A., Keating, E., Knaus, P., and Petersen, N.O. Signal transduction of bone morphogenetic protein receptors. Cell Signal 16, 291, 2004.
34. Foletta, V.C., Lim, M.A., Soosairajah, J., Kelly, A.P., Stanley, E.G., Shannon, M., He, W., Das, S., Massague, J., and Ber-nard, O. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. [erratum appears in J Cell Biol 27, 421, 2003 Note: Soosairaiah Juliana [corrected to Soo-sairajah Juliana]]. J Cell Biol 162, 1089, 2003.
35. Wallner, M., Hanchar, H.J., and Olsen, R.W. Ethanol en-hances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc Natl Acad Sci USA 100, 15218, 2003